INCYTE Executive and Leadership Team

Bill Meury, the Chief Executive Officer at INCYTE, directs the overarching corporate strategy and long-term vision for the biopharmaceutical organization. Overseeing the commercialization of critical therapeutics like JAKAFI and Iclusig, the Chief Executive Officer ensures alignment between research milestones and market delivery. This leadership role involves constant engagement with the Board to prioritize capital allocation toward high-impact oncology programs. By fostering a culture of scientific rigor, Bill Meury drives the company toward sustainable growth within the competitive United States pharmaceutical landscape. The Chief Executive Officer manages the executive team to ensure operational excellence across all departments. Through strategic oversight of the drug development pipeline, Meury secures the future of the company as a leader in kinase inhibitor technology. This executive presence guarantees that the organization remains focused on delivering life-changing treatments to patients suffering from myelofibrosis and other complex cancers.

Suketu Upadhyay, the Chief Financial Officer & Executive VP at INCYTE, manages the financial health and fiscal planning of the corporation. Overseeing global financial reporting and investor relations, the Chief Financial Officer & Executive VP ensures the stability required to fund intensive research and development cycles. This role involves rigorous analysis of market trends to optimize the commercial performance of JAKAFI and Iclusig. By architecting robust financial frameworks, Suketu Upadhyay supports the expansion of the company's therapeutic portfolio. The Chief Financial Officer & Executive VP collaborates with the executive leadership to align budgetary resources with long-term clinical goals. Through disciplined capital management, Upadhyay strengthens the balance sheet to facilitate ongoing innovation. This leadership position remains vital for maintaining investor confidence while the company pursues aggressive growth strategies within the biopharmaceutical sector, ensuring that financial resources directly translate into meaningful patient outcomes.

Suky Upadhyay, the Executive Vice President & Chief Financial Officer at INCYTE, oversees the strategic financial operations and risk management frameworks that sustain the company's biopharmaceutical mission. Managing the treasury and corporate accounting functions, the Executive Vice President & Chief Financial Officer ensures that the organization maintains the liquidity necessary for long-term clinical trials. This role involves evaluating the economic viability of new therapeutic candidates and optimizing the commercialization strategy for existing products. By providing transparent financial reporting, Suky Upadhyay drives accountability and trust with shareholders. The Executive Vice President & Chief Financial Officer works closely with the leadership team to ensure that financial planning supports the company's commitment to oncology innovation. Through meticulous oversight of operational costs, Upadhyay maximizes the efficiency of the company's research investments. This leadership position remains critical for navigating the complex financial landscape of the pharmaceutical industry while ensuring the company achieves its growth objectives.

Pablo Cagnoni, the President, Global Head of Research & Development at INCYTE, directs the scientific discovery and clinical development programs that define the company's therapeutic pipeline. Overseeing the transition of molecules from the laboratory to clinical trials, the President, Global Head of Research & Development ensures that the company maintains a robust portfolio of kinase inhibitors. This role involves leading the global research teams to identify novel treatments for myelofibrosis and other hematologic malignancies. By fostering collaboration between internal scientists and external partners, Pablo Cagnoni drives the rapid advancement of high-potential drug candidates. The President, Global Head of Research & Development collaborates with the medical and commercial teams to ensure that scientific breakthroughs translate into viable patient therapies. Through strategic oversight of the R&D budget, Cagnoni ensures that the company remains at the forefront of biopharmaceutical innovation. This leadership role is essential for maintaining the company's reputation for scientific excellence and therapeutic impact.

Soni Basi, the Executive Vice President & Chief Human Resources Officer at INCYTE, directs the talent acquisition and organizational development strategies necessary to support a high-growth biopharmaceutical environment. Overseeing the cultivation of a diverse and skilled workforce, the Executive Vice President & Chief Human Resources Officer ensures that the company attracts top-tier scientific and commercial talent. This role involves designing performance management systems that incentivize innovation in the development of kinase inhibitors. By fostering an inclusive corporate culture, Soni Basi drives employee engagement and retention across all operational sites. The Executive Vice President & Chief Human Resources Officer collaborates with the C-suite to align human capital initiatives with the broader mission of delivering oncology therapeutics. Through strategic workforce planning, Basi supports the company's ability to scale operations effectively. This leadership function remains essential for maintaining the intellectual capital required to sustain the company's competitive edge in the pharmaceutical industry.

Andrew Blyton, the Vice President & Chief Information Officer at INCYTE, architects the digital infrastructure and data security protocols that underpin the company's research and commercial operations. Overseeing the integration of advanced analytics into the drug discovery process, the Vice President & Chief Information Officer ensures that clinical data remains secure and accessible for development teams. This role involves managing the technological systems that support the distribution of JAKAFI and Iclusig across the United States. By implementing scalable cloud solutions, Andrew Blyton drives operational efficiency and data-driven decision-making throughout the organization. The Vice President & Chief Information Officer collaborates with the research and development departments to streamline the digital workflows essential for modern biopharmaceutical success. Through proactive cybersecurity measures, Blyton protects the company's intellectual property and patient information. This leadership role ensures that the technological foundation remains robust enough to support the company's ambitious therapeutic development goals.

Steven Stein, the Executive VP, Chief Medical Officer & Head of Late-stage Development at INCYTE, oversees the clinical safety and regulatory strategy for the company's late-stage therapeutic assets. Managing the interactions with health authorities, the Executive VP, Chief Medical Officer & Head of Late-stage Development ensures that clinical trials for JAKAFI and other pipeline products meet the highest standards of efficacy and patient safety. This role involves designing the clinical protocols that support the successful registration and commercial launch of new oncology treatments. By leading the medical affairs team, Steven Stein drives the communication of clinical data to the medical community. The Executive VP, Chief Medical Officer & Head of Late-stage Development collaborates with the research teams to ensure that late-stage development remains aligned with patient needs. Through rigorous clinical oversight, Stein secures the regulatory pathways necessary for the company to deliver life-saving therapies to patients across the United States.